Skip to main content
OpenTrials
Completed

NCT Number: NCT03966911

Performance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and Pediatrics

The purpose of this study is to demonstrate the performance of the Guardian™ Sensor (3) with an advanced algorithm in subjects age 2 - 80 years, for the span of 170 hours (7 days).

Completed

Looking for future studies?

Notify Me

Key information

Age range

2 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

AMCR Institue, Escondido, California, United States

Loading trial locations.

About this study

The study is a multi-center, prospective, single-sample correlational design without controls. The purpose of this study is to demonstrate the performance of the Guardian™ Sensor (3) with an advanced algorithm in subjects age 2 - 80 years, for the span of 170 hours (7 days).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Individual is 2 - 80 years of age at time of enrollment
  • A clinical diagnosis of type 1 or 2 diabetes for a minimum of 6 months duration as determined via medical record or source documentation by an individual qualified to make a medical diagnosis
  • Adequate venous access as assessed by investigator or appropriate staff
  • Subjects participating in the high and low glucose challenges must have an insulin carbohydrate ratio(s) and insulin sensitivity ratio. Subjects without ratios may participate under observation only

Exclusion criteria

  • Subject will not tolerate tape adhesive in the area of Guardian™ Sensor (3) placement as assessed by a qualified individual.
  • Subject has any unresolved adverse skin condition in the area of sensor or device placement (e.g., psoriasis, rash, Staphylococcus infection)
  • Subject is actively participating in an investigational study (drug or device) wherein they have received treatment from an investigational study (drug or device) in the last 2 weeks
  • Subject is female and has a positive pregnancy screening test
  • Female of child bearing age and who is sexually active should be excluded if she is not using a form of contraception deemed reliable by investigator
  • Subject is female and plans to become pregnant during the course of the study
  • Subject has had a hypoglycemic seizure within the past 6 months prior to enrollment
  • Subject has had hypoglycemia resulting in loss of consciousness within the past 6 months prior to enrollment.
  • Subject has had an episode of diabetic ketoacidosis (DKA) within the past 6 months prior to enrollment.
  • Subject has a history of a seizure disorder
  • Subject has central nervous system or cardiac disorder resulting in syncope
  • Subject has a history of myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack (TIA), cerebrovascular accident (CVA), angina, congestive heart failure, ventricular rhythm disturbances or thromboembolic disease
  • Subject has a hematocrit (Hct) lower than the normal reference range (please note that patients may use prior blood draw from routine care as long as done within 6 months of screening and report of lab placed with subject source documents)
  • Subject has a history of adrenal insufficiency
  • Subject is a member of the research staff involved with the study.

Treatment and study plan

Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter

Device

Continuous Glucose Monitoring and frequent sample testing

Primary outcomes

  1. Percentage of Readings Within 20% Agreement

    Time frame: 7 days (170 hours)

    Mean of daily percentage of sensor values within 20% of Yellow Springs Instrument (YSI™*) reference value (within 20 mg/dL if sensor values < 80 mg/dL), across all participants and all Frequent Sample Testing (FST) days. Note Self-Monitoring Blood Glucose (SMBG) was used for age 2-6, instead of YSI.

Sponsors and collaborators

Lead sponsor

Medtronic MiniMed, Inc.

Industry

Registry information

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
May 29, 2019
Registry last updated
Jun 7, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.